Bosley Katrine 4
4 · Editas Medicine, Inc. · Filed Oct 3, 2018
Insider Transaction Report
Form 4
Bosley Katrine
DirectorPresident and CEO10% Owner
Transactions
- Sale
Common Stock
2018-10-01$30.64/sh−6,234$191,010→ 1,246,732 total - Sale
Common Stock
2018-10-01$31.44/sh−5,766$181,283→ 1,240,966 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended.
- [F2]This transaction was executed in multiple trades at prices ranging from $30.20 to $31.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $31.20 to $31.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.